Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers

	Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers
	Jiang, MH; Shi, WF; Zhang, Q; Wang, XH; Guo, MG; Cui, ZF; Su, CQ; Yang, Q; Li, YM; Sham, J
刊名	CLINICAL CANCER RESEARCH
	2006
卷号	12 期号:20 页码:6179-6185
通讯作者	Qian, QJ (reprint author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Lab Viral & Gene Therapy, 225 Changhai Rd, Shanghai 200438, Peoples R China.,qianqj@sino-gene.cn
英文摘要	Purpose: therapeutic monoclonal antibody is increasingly applied in many clinical applications, although complicated technologies and high cost still limit their wide applications. To obtain the sustained serum antibody concentration with one single injection and lower the cost of antibody protein therapy, an adenovirus-mediated full-length antibody gene therapy was developed. Experimental Design: Full-length antibody light-chain and heavy-chain sequences were linked with internal ribosome entry site and constructed into adenoviral vector under the control of cytomegalovirus promoter. Antibody expression in vitro and in vivo were tested with ELISA, and its antitumor efficacy was evaluated in SKOV-3-inoculated nude mice. Results: Ad5-TAb - generated anti-HER-2 antibody presented the similar binding specificity with commercial trastuzumab. A single i.v. injection of 2 x 10(9) plaque-forming units of Ad5-TAb per mouse resulted in not only a sustained over 40 mu g/mL serum antibody level for at least 4 weeks but also significant tumor elimination in the ovarian cancer SKOV-3-inoculated nude mice. Conclusions: An in vivo full-length antibody gene delivery system allows continuous production of a full-length antibody at high concentration after a single administration. Bioactive antibody macromolecules can be generated via gene transfer in vivo. All the data suggest that this novel adenovirus-mediated antibody gene delivery can be used for the exploitation of antibodies, without being hampered by the sophisticated antibody manufacture techniques and high cost, and, furthermore, can shorten the duration and reduce the expense of antibody developments.
学科主题	Oncology
类目[WOS]	Oncology
关键词[WOS]	MONOCLONAL-ANTIBODY ; BREAST-CANCER ; MAMMALIAN-CELLS ; 2A PEPTIDE ; CHO-CELLS ; EXPRESSION ; TRASTUZUMAB ; VECTOR ; FRAGMENTS ; EFFICACY
收录类别	SCI
语种	英语
WOS记录号	WOS:000241468300038
内容类型	期刊论文
版本	出版稿
源URL	[http://202.127.25.143/handle/331003/1794]
专题	上海生化细胞研究所_上海生科院生化细胞研究所
推荐引用方式 GB/T 7714	Jiang, MH,Shi, WF,Zhang, Q,et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers[J]. CLINICAL CANCER RESEARCH,2006,12(20):6179-6185.
APA	Jiang, MH.,Shi, WF.,Zhang, Q.,Wang, XH.,Guo, MG.,...&Qian, QJ.(2006).Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers.CLINICAL CANCER RESEARCH,12(20),6179-6185.
MLA	Jiang, MH,et al."Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers".CLINICAL CANCER RESEARCH 12.20(2006):6179-6185.